Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 32INDUSTRY 7OTHER_GOV 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Paget's Disease, Mammary 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Interventional × Docosahexaenoic Acids × Clear all
NCT01849250 2021-12-28

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

National Cancer Institute (NCI)

Phase 2 Completed
65 enrolled 11 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Paget's Disease, Mammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡